Drug Profile
GLS 5100
Alternative Names: GLS-5100Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator GeneOne Life Science
- Developer GeneOne Life Science; University of Pennsylvania
- Class DNA vaccines; Varicella vaccines
- Mechanism of Action Glycoprotein inhibitors; Immediate early protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Herpes zoster
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for preclinical development in Herpes-zoster(Prevention) in South Korea (Parenteral)
- 16 Jun 2020 Preclinical development in Herpes-zoster (Prevention) is underway in South Korea (Parenteral) (GeneOne Life Science pipeline, June 2020)
- 28 Nov 2019 No recent reports of development identified for preclinical development in Herpes-zoster(Prevention) in South Korea (Parenteral)